Cathie Wood’s ARK Genomic Revolution ETF has invested $15.3 million in Ionis Pharmaceuticals recently, despite a nearly 37% drop in its stock after a late-stage trial failure for eplontersen, a treatment for a rare heart disease. Wood’s investments seem to reflect a long-term belief in Ionis’s potential, especially following FDA approval of its drug, Tryngolza, for severe hypertriglyceridemia (sHTG), significantly expanding its market potential. Ionis is pivoting from an R&D-focused company to fully commercialize its products, anticipating substantial revenue growth despite increasing costs. While the company has a promising pipeline, concerns remain over its marketing expenses and potential for future setbacks.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://finance.yahoo.com/healthcare/articles/cathie-wood-just-bet-big-142000026.html
